A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
作者信息
Voorhees Peter M, Sborov Douglas W, Laubach Jacob, Kaufman Jonathan L, Reeves Brandi, Rodriguez Cesar, Silbermann Rebecca, Costa Luciano J, Anderson Larry D, Nathwani Nitya, Shah Nina, Bumma Naresh, Efebera Yvonne A, Holstein Sarah A, Costello Caitlin, Jakubowiak Andrzej, Wildes Tanya M, Orlowski Robert Z, Shain Kenneth H, Cowan Andrew J, Dinner Shira, Gries Katharine S, Pei Huiling, Cortoos Annelore, Patel Sharmila, Lin Thomas S, Usmani Saad Z, Richardson Paul G
机构信息
Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
出版信息
Future Oncol. 2025 Jan;21(1):25-49. doi: 10.1080/14796694.2024.2408909. Epub 2024 Oct 25.
Abstract
摘要
相似文献
1
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.达雷妥尤单抗联合来那度胺、硼替佐米及地塞米松用于新诊断多发性骨髓瘤患者的GRIFFIN研究最终分析的通俗语言总结。
Future Oncol. 2025 Jan;21(1):25-49. doi: 10.1080/14796694.2024.2408909. Epub 2024 Oct 25.
2
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.GRIFFIN研究中，达雷妥尤单抗联合来那度胺/硼替佐米/地塞米松用于适合移植的新诊断多发性骨髓瘤黑人患者的通俗易懂总结。
Future Oncol. 2022 Dec;18(40):4443-4456. doi: 10.2217/fon-2022-0775. Epub 2023 Feb 17.
3
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.PERSEUS 研究中达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松治疗初诊多发性骨髓瘤的通俗语言摘要。
Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
4
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤患者（GRIFFIN）：一项开放标签、随机、2 期试验的最终分析。
Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11.
5
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.在新诊断的多发性骨髓瘤中，用包含达雷妥尤单抗和来那度胺的四联诱导治疗进行干细胞动员的结果：来自 MASTER 和 GRIFFIN 试验的结果。
Transplant Cell Ther. 2023 Mar;29(3):174.e1-174.e10. doi: 10.1016/j.jtct.2022.11.029. Epub 2022 Dec 6.
6
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.达雷妥尤单抗联合来那度胺、硼替佐米和地塞米松治疗新诊断多发性骨髓瘤：GRIFFIN 研究中血管血栓事件的分析。
Br J Haematol. 2022 Nov;199(3):355-365. doi: 10.1111/bjh.18432. Epub 2022 Sep 16.
7
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.达雷妥尤单抗、来那度胺、硼替佐米和地塞米松用于适合移植的新诊断多发性骨髓瘤：GRIFFIN 试验。
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
8
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.达雷妥尤单抗联合 RVd 方案治疗初诊多发性骨髓瘤：GRIFFIN 研究安全性预试验队列的最终分析。
Blood Adv. 2021 Feb 23;5(4):1092-1096. doi: 10.1182/bloodadvances.2020003642.
9
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.达雷妥尤单抗、来那度胺、硼替佐米及地塞米松联合治疗新诊断的适合移植的多发性骨髓瘤患者的健康相关生活质量：GRIFFIN研究的患者报告结局
Am J Hematol. 2024 Jul;99(7):1257-1268. doi: 10.1002/ajh.27326. Epub 2024 Apr 15.
10
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.依洛尤单抗、来那度胺、硼替佐米、地塞米松和自体造血干细胞移植治疗新诊断多发性骨髓瘤（GMMG-HD6）：一项随机、3 期试验的结果。
Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6.
引用本文的文献
1
Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.在英国，elranatamab与现实世界中针对三重暴露复发和难治性多发性骨髓瘤的治疗结果比较。
BMC Cancer. 2025 Jul 25;25(1):1219. doi: 10.1186/s12885-025-14624-9.
Zotero 插件